-
Meetings
EAACI Congress Geneva 2012
- Business meeting
Epidemiology IG Businness Meeting Geneva 2012- Epidemiology Sessions
- Epidemiology related sessions Geneva 2012
EAACI Congress Milan 2013
- Business meeting
- Epidemiology IG Business Meeting Milan 2013
View our minutes from EAACI 2013 in Milan under 'Resources'
- Epidemiology Sessions
- Epidemiology related sessions Milan 2013
EAACI Congress Copenhagen 2014
- Business meeting
View our minutes from EAACI 2014 in Copenhagen under 'Resources'
EAACI Congress Vienna 2016
- Business meeting
-
View our minutes from EAACI 2016 in Vienna under 'Resources'
Last updated: 24 November 2016 -
Postgraduate Courses
Post Graduate Course 2012: Epidemiology for the Clinical Allergist
The Epidemiology IG held its first post graduate course on ‘Epidemiology for the Clinical Allergist’ at the EAACI Congress 2012 in Geneva. The feedback from participants was excellent and we plan to hold similar PG courses at future EAACI meetings.
Presentations from the course can be found under "Resources".
From left to right: Michael Perkin, Kirsty Logan, Carsten Flohr, Christian Apfelbacher, Paolo Matricardi, George KonstantinouPost Graduate Course 2013: Conducting a systematic review/metaanalysis – working with the Cochrane Collaboration
The second postgraduate course "Conducting a systematic review/metaanalysis - working with the Cochrane Collaboration" was held at the EAACI 2013 Congress in Milan.
Presentations from the course can be found under "Resources".
Last updated: 07 August 2015 -
Allergy Registry Task Force (A-reg)
Allergic diseases, such as asthma, hay fever, eczema, and food allergies, affect around 20% of children in European countries and early onset severe disease often persists into adulthood. The impact on quality of life and health care resources is comparable to diabetes and rheumatoid arthritis. Furthermore, immediate allergic reactions, for instance to foods and drugs, can be life threatening.
Over past years, patient, disease and treatment registries have become increasingly recognised as important tools to improve standards of clinical care, for instance through data on the short and long-term efficacy and safety of therapies, especially where running a clinical trial is difficult due to the need for long-term follow up and also in case of rare conditions. Registry data also allow to analyse quality of care, for instance by benchmarking medical care against current evidence-based guidelines.
While a number of medical specialties developed disease and treatment registries years back, for instance for diabetes and cardiovascular disease, there is still a lack of such registries within the allergy field, although a few national initiatives have recently been started (eg. drug allergy (Pascal Demoly, France; http://www.dahd.net/), anaphylaxis (Margitta Worm, Germany; http://www.anaphylaxie.net), and chronic hand dermatitis (Christian Apfelbacher, Germany; http://www.carpe.dermis.net). Even where such national projects exist, there clearly is potential and need to extend such registries across European countries, using a standardised methodology to optimise the potential benefit of these registries for clinicians and researchers but also to ensure patient safety across European country borders.
We therefore set up a Task Force on allergic disease registries in late 2011 with the overall objective to provide a platform for the formation of allergic disease registries across EU country borders to develop suitable monitoring tools for use in both clinical practice and research. We also want to help standardisation of data collection on allergic diseases, diagnosis and treatment and ultimately improve allergic disease and allergen exposure management.
The A-reg project will initially focus on two national allergic disease registries to grow into pan-European projects, namely anaphylaxis (Prof M Worm) and drug allergy (Prof Pascal Demoly). Two further therapy-related projects are planned to be started de novo, one on cutaneous and systemic side effects of immunotherapy (Dr Moises Calderon) and one on immunosuppressive therapies in patients with severe atopic dermatitis (Dr Carsten Flohr). The main advantage of starting a registry in several European reference centres at the same time is that the same methodology ensures direct comparability from the start. We also plan to incorporate biobanking in all of these registries for research purposes.
It is anticipated that these four projects will inform the development of further allergic disease/therapy registries, especially with regard to methodology (data collection, software use, data analysis and ethics).
One of the remits of the EAACI Allergy Registry (A-Reg) Task Force is to collect data on existing allergy registries across Europe. EAACI was proud to be a collaborating partner of the European Joint Action PARENT (May 2012-May 2015), an important EU-funded research programme aiming to provide documents and tools for implementation of interoperable and cross-border enabled patient registries. Over the course of the PARENT JA, The Methodological Guidelines and Recommendations for Efficient and Rational Governance of Patient Registries (http://parent-wiki.nijz.si/) have been developed as well as two complete versions of the Registry of Registries/RoR (http://www.parent-ror.eu). The first one was based upon an online questionnaire, which collected metadata on EU-level patient registries and included a complete directory with various browsing functions. The second version of RoR included the Nomination function which allows registry holders to nominate new organisations and registries. It consisted of Assessment/Improvement and Comparison tool which enables registry's quality and interoperability assessment (based on knowledge compiled in the Guidelines) and registry information comparison.
Although PARENT JA project has oficially ended, PARENT JA team continues to develop project's deliverables. PARENT JA team invites registry holders and administrators to join the Registry of Registries platform and use tools and documents of significant utility, not only for those involved in the work in patient registries, but also for those trying to create a new one.
A-reg Task Force members:
Dr Christian Apfelbacher, Chair
Dr Carsten Flohr, Secretary
Prof Nikos Papadopoulos
Prof Peter Burney
Dr Moises Calderon
Dr George Konstantinou
Prof Pascal Demoly
Prof Aziz Sheikh
Prof Margitta Worm
If you would like to learn more about A-reg, please contact carsten.flohr@kcl.ac.uk.Last updated: 07 July 2016 -
Task Force: Overview of systematic reviews in allergy epidemiology (OSRAE)
Description of Task Force:
There are several documentations of expert opinions about achievements and gaps in allergy research such as the recently drafted EAACI Position Paper or the WAO White Book. These often incorporate evidence from systematic reviews and meta-analyses which gain more and more importance in the attempt to synthesize previously published evidence. This Task Force will – to our knowledge for the first time – systematically identify systematic reviews and meta-analyses conducted on risk or protective factors for allergic disease. Articles will be searched in PubMed and possibly other databases. The content of retrieved articles will be evaluated for relevance to the project. The evidence from the relevant articles will be judged against the list of exposures deemed important by expert opinion. Thus, gaps in the systematic synthesis of previously published research on allergies can be identified.
View our meeting minutes fom EAACI in Milan 2013 under - 'Resources'
View our meeting minutes fom EAACI in Copenhagen 2014 under - 'Resources'Last updated: 19 January 2016
GO TO
FULLSCREEN
FULLSCREEN